[go: up one dir, main page]

PE20000241A1 - Composicion farmaceutica de proteinas erizo y empleo del mismo - Google Patents

Composicion farmaceutica de proteinas erizo y empleo del mismo

Info

Publication number
PE20000241A1
PE20000241A1 PE1999000072A PE00007299A PE20000241A1 PE 20000241 A1 PE20000241 A1 PE 20000241A1 PE 1999000072 A PE1999000072 A PE 1999000072A PE 00007299 A PE00007299 A PE 00007299A PE 20000241 A1 PE20000241 A1 PE 20000241A1
Authority
PE
Peru
Prior art keywords
contain
protein
support
pharmaceutical composition
erizo
Prior art date
Application number
PE1999000072A
Other languages
English (en)
Inventor
Apollon Papadimitriou
Kurt Lang
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of PE20000241A1 publication Critical patent/PE20000241A1/es

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA PROTEINA ERIZO (HEDGEHOG) UNIDA A UN SOPORTE HIDROFILICO BIOCOMPATIBLE Y BIODEGRADABLE, UTILIZANDOSE DE 0,1 mg/ml A 100 mg/ml. EL SOPORTE ES UN POLIMERO QUE SE CARACTERIZA a)POR SER UN ANION A CAUSA DE INTERACCIONES IONICAS; b)NO DESNATURALIZAR LA PROTEINA; c)CONTENER DE 0,1 A 2 IONES POR MONOMERO EN CONDICIONES NEUTRAS; d)CONTENER CARGAS EN FORMA DE GRUPOS DE CARACTER ACIDO; e)PESO MOLECULAR DE 50 000 DALTON; f)NO CONTENER AGAROSA. EL SOPORTE SE COMPONE DE UNA MATRIZ ORGANICA DE SOPORTE HIDROFILICO (ACIDO HIALURONICO) O UN POLISACARIDO ANIONICO O ACIDO HIALURONICO O DE UN FOSFATO INORGANICO INSOLUBLE. LA COMPOSICION SE CARACTERIZA POR EL pH DE 4-10; Y ADICIONALMENTE PUEDE CONTENER ARGININA O IONES ARGINILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA PROTEINA ERIZO ES RESPONSABLE DE LA FORMACION DE ESTRUCTURAS EN LA EMBRIOGENESIS Y SE LIBERA EN FORMA LOCAL EN HUESOS Y CARTILAGOS
PE1999000072A 1998-02-04 1999-02-01 Composicion farmaceutica de proteinas erizo y empleo del mismo PE20000241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98101893 1998-02-04

Publications (1)

Publication Number Publication Date
PE20000241A1 true PE20000241A1 (es) 2000-04-08

Family

ID=8231349

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000072A PE20000241A1 (es) 1998-02-04 1999-02-01 Composicion farmaceutica de proteinas erizo y empleo del mismo

Country Status (8)

Country Link
AR (1) AR014530A1 (es)
BR (1) BR9900523A (es)
HR (1) HRP990036A2 (es)
ID (1) ID22356A (es)
PE (1) PE20000241A1 (es)
PL (1) PL331201A1 (es)
TR (1) TR199900197A2 (es)
ZA (1) ZA99887B (es)

Also Published As

Publication number Publication date
PL331201A1 (en) 1999-08-16
ZA99887B (en) 1999-08-04
HRP990036A2 (en) 1999-08-31
BR9900523A (pt) 2000-05-02
AR014530A1 (es) 2001-02-28
TR199900197A2 (xx) 1999-08-23
ID22356A (id) 1999-10-07

Similar Documents

Publication Publication Date Title
Arakawa et al. Photopolymerizable chitosan–collagen hydrogels for bone tissue engineering
Chenite et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ
Xu et al. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2
Lam et al. Evaluation of cell-laden polyelectrolyte hydrogels incorporating poly (L-Lysine) for applications in cartilage tissue engineering
EP2106263B1 (en) Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
Mohandas et al. Chitosan–hyaluronic acid/VEGF loaded fibrin nanoparticles composite sponges for enhancing angiogenesis in wounds
Thomopoulos et al. bFGF and PDGF-BB for tendon repair: controlled release and biologic activity by tendon fibroblasts in vitro
Park et al. Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering
Tianyuan et al. A smart MMP13‐responsive injectable hydrogel with inflammatory diagnostic logic and multiphase therapeutic ability to orchestrate cartilage regeneration
EP2324065B1 (en) A heparan sulphate which binds bmp2
Abbah et al. In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template
Guo et al. Multiscale design and synthesis of biomimetic gradient protein/biosilica composites for interfacial tissue engineering
Matricardi et al. Polysaccharide hydrogels: Characterization and biomedical applications
BRPI0416590A (pt) excipientes em veìculos de distribuição de fármacos
BRPI0416032A (pt) excipientes em veìculos de distribuição de fármacos
KR20040047746A (ko) 향상된 골 이식물
RU2012122334A (ru) Композиция полисахаридного геля, обладающего многоступенчатой доставкой биоактивных веществ
BRPI0411678A (pt) nanopartìculas de ácido hialurÈnico
AU4344899A (en) Pharmaceutical composition of hedgehog proteins and use thereof
Coulter et al. Enzyme‐triggered l‐α/d‐peptide hydrogels as a long‐acting injectable platform for systemic delivery of HIV/AIDS drugs
Thankam et al. Hybrid interpenetrating hydrogel network favoring the bidirectional migration of tenocytes for rotator cuff tendon regeneration
Wu et al. Development of a chitosan–polyglutamate based injectable polyelectrolyte complex scaffold
Cardoso et al. Bifunctional naringenin-laden gelatin methacryloyl scaffolds with osteogenic and anti-inflammatory properties
WO2021042777A1 (zh) 一种治疗肿瘤的多组分凝胶缓释药物组合物
SE9603480L (sv) Beredningsform för svårlösliga läkemedel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal